Background: Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear.Objectives: Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases.

Objective-Sepsis is a major cause of death for intensive care patients. High concentrations of inflammatory cytokines are characteristic of severe systemic inflammation and activated monocytes are their predominant cellular source. To identify targets for antiinflammatory intervention, we investigated the response of human macrophages to inflammatory and antiinflammatory mediators. Methods and Results-We profiled gene expression in human macrophages exposed to lipopolysaccharide (LPS) and interferon (IFN)-␥ in the presence or absence of recombinant activated protein C (APC) or IL-10 and identified Wnt5A as one of the transcripts most highly induced by LPS/IFN-␥ and suppressed by APC and IL-10. We confirmed regulation of Wnt5A protein in macrophages and detected it in sera and bone marrow macrophages of patients with severe sepsis. We established that a functional Wnt5A/frizzled-5/CaMKII signaling pathway was essential for macrophage inflammatory activation. To prove the essential contribution of Wnt5A we measured inflammatory cytokines after stimulation with Wnt5A, silenced Wnt5A by siRNA, and blocked receptor binding with soluble Frizzled-related peptide-1 (sFRP1). Key Words: geneexpression Ⅲ macrophages Ⅲ activated protein C S epsis is a suspected or proven infection with a systemic inflammatory response. In severe sepsis, organ dysfunction also occurs and it is associated with a high mortality and morbidity. Severe sepsis still causes about 9.3% of all deaths in the USA. 1,2 Conclusion-Wnt5A is critically involved in inflammatory macrophage See accompanying article on page 400During sepsis, the extent of plasma protein C depletion correlates with the severity of the outcome. 3 In animal studies 4 and clinical trials APC prevented death from severe sepsis or septic shock. 5 Although this beneficial effect of APC is mostly ascribed to its anticoagulant properties, antiinflammatory effects of APC have also been proposed. 6 The direct modulation of inflammation by APC has recently been described in gene expression profiling studies with human endothelial cells. 7,8 Recently, recombinant human APC has been introduced as a therapeutic agent for treatment of patients with severe sepsis because of its unique anticoagulant and antiinflammatory properties; however, the exact mechanism of antiinflammatory action is still unknown. 9 Macrophages play a central role in inflammation by responding to and releasing of numerous inflammatory cytokines and chemokines, leading to severe systemic inflammation and septic shock. However, the knowledge of antiinflammatory interactions on the level of monocytes/macrophages is scant. Therefore, we decided to expand our investigations on antiinflammatory effects of APC on this cellular system. In the present study, we were using a whole genome expression analysis approach, to define novel targets of APC in an in vitro model of inflammatory macrophage activation. Using probes obtained from human macrophages stimulated by INF-␥ (IFN-␥) and endotoxin (LPS), we consistently found Wnt5A to ...

Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which – combined with age, history of asthma bronchiale, and five symptoms during primary infection – is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals with COVID-19. Our results highlight the benefit of measuring Igs for the early identification of patients at high risk for PACS, which facilitates the study of targeted treatment and pathomechanisms of PACS.

Highlights d Systems analysis of the innate immune responses in COVID-19 up to 47 days after onset d Surge of CD169 + and depletion of CD16 + CD14 À monocytes early after symptom onset d High levels of inflammatory cytokines and immature neutrophils in severe COVID-19 d Persistent inflammation in late severe cases, while normalization in mild cases

Reactive hemophagocytic syndrome (RHS) is a disease of overwhelming macrophage activity triggered by infection, malignancy or autoimmune disorders. Currently used laboratory markers for the quantitative assessment of monocyte/macrophage activation lack lineage-restricted expression patterns and thus specificity. Serum levels of the macrophage specific scavenger receptor CD163 were determined by enzyme-linked immunosorbent assay (ELISA) and were found to be highly increased in patients with RHS (median 39.0 mg/L). Significantly lower levels were determined in patients with sepsis (median 9.1 mg/L), acute mononucleosis (median 8.2 mg/L), Leishmania infection (median 6.7 mg/L) and healthy controls (median 1.8 mg/L). Follow-up of patients with a relapsing course of the disease revealed close correlations of sCD163 with clinical disease activity, serum ferritin and other markers of macrophage activity. Large sinusoidal accumulations of CD163 expressing macrophages actively engaged in phagocytosis of blood cells were detected in spleen sections of RHS patients. Our data suggests sCD163 to be a macrophage-specific marker in patients with disorders of inappropriate macrophage activation.